Inventiva S.A. Annual Report - How They Did This Year

I’m breaking down Inventiva S.A.’s latest annual report into plain English. My goal is to help you decide if this company fits your investment goals.

1. What does this company do?

Inventiva is a biotech company researching treatments for metabolic, inflammatory, and fibrotic diseases. Their star player is lanifibranor, a pill currently in late-stage (Phase III) testing for a liver disease called MASH. As of December 31, 2025, they had 193.2 million shares outstanding. Their main focus is the NATiV3 trial, which is the final hurdle before they can ask regulators in the US and Europe for permission to sell the drug.

2. Financial performance

Inventiva is currently spending money rather than making it. They reported a loss of about €112.5 million this year. Since they have no products on the market, they earn almost no revenue. Most of their money comes from small research fees and payments from licensing deals. Their biggest expense is research and development, which cost about €95 million as they fund the NATiV3 trial. To keep going, they rely on partners like CTTQ and Hepalys Pharma, who paid them upfront to help develop lanifibranor in China and Japan.

3. Major wins and challenges

The big story is survival. In 2024 and 2025, the company raised about €94 million through private sales and debt to keep the lights on. While this prevented a cash crisis, it came at a cost: they issued more shares, which reduces your ownership percentage as an existing investor. This is the price they pay to keep the NATiV3 trial running without product sales.

4. Financial health

The company is walking a tightrope. By the end of 2025, they had about €65 million in cash. They spend roughly €20–€25 million every three months. This means their cash will run out soon unless they hit clinical milestones that trigger payments from partners. If these milestones are delayed, the company may need to issue even more shares or restructure their debt to stay afloat.

5. Key risks

Drug development is an "all-or-nothing" game. If lanifibranor fails its final tests, the company’s value could collapse because they have no other advanced drugs in their pipeline. Also, the constant need for cash creates a "dilution overhang," where investors worry about more shares being issued, which can keep the stock price down. Finally, as a French company, they face risks from currency swings between the Euro and the US Dollar.

6. Competitive positioning

They are fighting for space in a crowded market. Giants like Madrigal Pharmaceuticals already have an approved MASH drug. Inventiva hopes their drug works better than the competition. Their success depends on proving this in the NATiV3 trial to grab a piece of this massive market.

7. Future outlook

The plan is simple: finish the NATiV3 trial and prepare for regulators. They expect key results in 2026. Management wants to use this data to find a major partner or prove the drug is ready for market. Success depends on having enough cash to reach these results.

Note: This is a high-risk, high-reward sector. Always watch the clinical trial results as the true heartbeat of this company, not just the bank balance. Before investing, ask yourself if you are comfortable with the possibility of further share dilution and the binary nature of clinical trial outcomes.